Literature DB >> 25922697

The challenge of using biomarkers and molecularly targeted drugs to improve cure rate in early stage non-small cell lung cancer.

Nevin Murray1.   

Abstract

Entities:  

Year:  2015        PMID： 25922697      PMCID： PMC4387405          DOI： 10.3978/j.issn.2072-1439.2015.01.49

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  22 in total

1.  Customized adjuvant phase II trial in patients with non-small-cell lung cancer: IFCT-0801 TASTE.

Authors:  Marie Wislez; Fabrice Barlesi; Benjamin Besse; Julien Mazières; Patrick Merle; Jacques Cadranel; Clarisse Audigier-Valette; Denis Moro-Sibilot; Laure Gautier-Felizot; François Goupil; Aldo Renault; Elisabeth Quoix; Pierre-Jean Souquet; Anne Madroszyck; Romain Corre; David Pérol; Franck Morin; Gérard Zalcman; Jean-Charles Soria
Journal:  J Clin Oncol       Date:  2014-03-17       Impact factor: 44.544

2.  Genetically informed lung cancer medicine.

Authors:  William Pao; A John Iafrate; Zengliu Su
Journal:  J Pathol       Date:  2010-10-25       Impact factor: 7.996

Review 3.  Small cell lung cancer: where do we go from here?

Authors:  Lauren Averett Byers; Charles M Rudin
Journal:  Cancer       Date:  2014-10-21       Impact factor: 6.860

4.  DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy.

Authors:  Ken A Olaussen; Ariane Dunant; Pierre Fouret; Elisabeth Brambilla; Fabrice André; Vincent Haddad; Estelle Taranchon; Martin Filipits; Robert Pirker; Helmut H Popper; Rolf Stahel; Laure Sabatier; Jean-Pierre Pignon; Thomas Tursz; Thierry Le Chevalier; Jean-Charles Soria
Journal:  N Engl J Med       Date:  2006-09-07       Impact factor: 91.245

5.  Clarifying the spectrum of driver oncogene mutations in biomarker-verified squamous carcinoma of lung: lack of EGFR/KRAS and presence of PIK3CA/AKT1 mutations.

Authors:  Natasha Rekhtman; Paul K Paik; Maria E Arcila; Laura J Tafe; Geoffrey R Oxnard; Andre L Moreira; William D Travis; Maureen F Zakowski; Mark G Kris; Marc Ladanyi
Journal:  Clin Cancer Res       Date:  2012-01-06       Impact factor: 12.531

6.  Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.

Authors:  Edward H Romond; Edith A Perez; John Bryant; Vera J Suman; Charles E Geyer; Nancy E Davidson; Elizabeth Tan-Chiu; Silvana Martino; Soonmyung Paik; Peter A Kaufman; Sandra M Swain; Thomas M Pisansky; Louis Fehrenbacher; Leila A Kutteh; Victor G Vogel; Daniel W Visscher; Greg Yothers; Robert B Jenkins; Ann M Brown; Shaker R Dakhil; Eleftherios P Mamounas; Wilma L Lingle; Pamela M Klein; James N Ingle; Norman Wolmark
Journal:  N Engl J Med       Date:  2005-10-20       Impact factor: 91.245

7.  Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer.

Authors:  Giorgio Vittorio Scagliotti; Purvish Parikh; Joachim von Pawel; Bonne Biesma; Johan Vansteenkiste; Christian Manegold; Piotr Serwatowski; Ulrich Gatzemeier; Raghunadharao Digumarti; Mauro Zukin; Jin S Lee; Anders Mellemgaard; Keunchil Park; Shehkar Patil; Janusz Rolski; Tuncay Goksel; Filippo de Marinis; Lorinda Simms; Katherine P Sugarman; David Gandara
Journal:  J Clin Oncol       Date:  2008-05-27       Impact factor: 44.544

8.  Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group.

Authors:  Jean-Pierre Pignon; Hélène Tribodet; Giorgio V Scagliotti; Jean-Yves Douillard; Frances A Shepherd; Richard J Stephens; Ariane Dunant; Valter Torri; Rafael Rosell; Lesley Seymour; Stephen G Spiro; Estelle Rolland; Roldano Fossati; Delphine Aubert; Keyue Ding; David Waller; Thierry Le Chevalier
Journal:  J Clin Oncol       Date:  2008-05-27       Impact factor: 44.544

Review 9.  Management of non-small-cell lung cancer: recent developments.

Authors:  Martin Reck; David F Heigener; Tony Mok; Jean-Charles Soria; Klaus F Rabe
Journal:  Lancet       Date:  2013-08-24       Impact factor: 79.321

Review 10.  Vinorelbine--a clinical review.

Authors:  R K Gregory; I E Smith
Journal:  Br J Cancer       Date:  2000-06       Impact factor: 7.640
View more
  1 in total

1.  SUMO1 promotes the proliferation and invasion of non-small cell lung cancer cells by regulating NF-κB.

Authors:  Changkang Ke; Kai Zhu; Ying Sun; Yunfeng Ni; Zhipei Zhang; Xiaofei Li
Journal:  Thorac Cancer       Date:  2018-11-04       Impact factor: 3.500
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.